Patients were more likely to have higher five-year and overall survival rates if their state had expanded Medicaid, ...

A targeted cancer drug niraparib, used in combination with hormone therapy, was found to reduce the risk of prostate tumor ...

Niraparib is a “maintenance” drug approved to keep certain types of cancer from coming back, including ovarian cancer, ...

Recurrent prostate cancer patients with luminal B tumors may benefit from hormone therapy added to radiation following surgery.

Carle Health is offering free cancer screenings in the coming months to help people detect the disease early, which can ...

Newer evidence from the POP-RT phase III trial did show that pelvic nodal radiation for high-risk, locally advanced prostate ...

While outcomes are improving, the report also found cancer incidence rates for younger people aged 30 to 49 are increasing.

Researchers found that late-stage, or distant-stage, prostate cancer is increasing across all age groups, including by approximately 3% annually in men under 55 and by 6% in those 55 and older. The ...

In men with prostate cancer, prophylactic whole pelvic radiotherapy does not improve OS compared to prostate-only dose-escalated radiotherapy.

SAN FRANCISCO -- For patients with recurrent prostate cancer, those with a certain subtype had clinically meaningful benefits ...

The importance of all health screenings is that they can detect issues early. Prostate cancer is one of the most common ...

September is Prostate Cancer Awareness Month. Mississippi has one of the highest prostate cancer mortality rates in the ...